. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: Am J Kidney Dis. 2018 Sep 21;73(1):82–89. doi: 10.1053/j.ajkd.2018.07.009

Table 2:

NEPTUNE and C-PROBE Patient Demographic and Baseline Clinical Characteristics

Variable	NEPTUNE	C-PROBE
No. of patients	380	938
Male sex	217 (59%)	419 (45%)
Age at baseline (years)	32 (14–52)	54 (33–65)
Under 18	125 (34%)	139 (15%)
Race
White	212 (57.6%)	528 (57%)
Black	86 (23.4%)	343 (37%)
Other	70 (19%)	50 (5%)
Hispanic/Latino	63 (17.1%)	71 (8%)
Baseline laboratory values
eGFR (mL/min/1.73m²)	85.4 (54.9–107.6)	52.7 (34.7–89.9)
UPCR	2.1 (0.6–4.5)
NEPTUNE Cohort
MN	68 (18.5%)
MCD	116 (31.5%)
FSGS	134 (36.4%)
IgAN	50 (13.6%)
C-PROBE Cohort
Diabetic nephropathy		152 (16%)
CAKUT		35 (4%)
Glomerular disease		389 (41 %)
Hypertensive nephropathy		95 (10%)
Other/Unknown		267 (28%)

Values shown are count (percentage) or median (interquartile range).

IQR=interquartile range, eGFR=estimated glomerular filtration rate, UPCR=urine protein creatinine ratio, MN= membranous nephropathy, MCD=minimal change disease, FSGS=focal segmental glomerularsclerosis, IgAN=immunoglobulin A nephropathy; CAKUT=congenital anomalies of the kidney and urinary tract; NEPTUNE, _______; C-PROBE, _______.